Asparlas
(Calaspargase Pegol-mknl)Phase 1Small molecule
This medication is an enzyme used alongside other chemotherapy drugs to treat acute lymphocytic leukemia (a blood cancer) in young patients. It works by blocking essential nutrients that cancer cells need to grow, thereby killing cancer cells or stopping their growth.[1] Asparlas is currently being investigated across 1 indication[3], with its most advanced program in Phase 1.[1]
Asparlas is one of 52 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.
1
Indications
4
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Nexavar
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia1 trial
T-cell acute lymphoblastic leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calaspargase Pegol-mknl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MM.D. Anderson Cancer Center